Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Company Deals

Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy

Fineline Cube Jan 15, 2026
Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Fineline Cube Jan 15, 2026
Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Fineline Cube Jan 15, 2026
Company Drug

Brii Biosciences Halts Development of Antibody Cocktail for COVID-19 Treatment

Fineline Cube Mar 28, 2023

Brii Biosciences has announced a strategic decision to end the manufacturing and further development of...

Company Deals

Berry Genomics Partners with MGI Tech to Advance Cancer Diagnostics and Screening

Fineline Cube Mar 28, 2023

Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary...

Company

PharmaBlock Expands US Presence with New R&D Facility in West Chester

Fineline Cube Mar 28, 2023

PharmaBlock, a leading company based in Nanjing (SHE: 300725), has announced the opening of a...

Company Drug

CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent

Fineline Cube Mar 28, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s...

Policy / Regulatory

NMPA Introduces Procedures to Adjust Chemical Generic Reference Preparations

Fineline Cube Mar 28, 2023

The National Medical Products Administration (NMPA) has released a document outlining procedures for the adjustment...

Company Deals

BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda

Fineline Cube Mar 28, 2023

Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with...

Company Medical Device

Acotec Scientific’s Vericor Receives Marketing Approval from Thailand FDA

Fineline Cube Mar 28, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...

Company Drug

CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008

Fineline Cube Mar 28, 2023

Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a...

Company Drug

Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review

Fineline Cube Mar 28, 2023

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing...

Company

Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs

Fineline Cube Mar 28, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022....

Policy / Regulatory

National ADR Monitoring Report Highlights Oncology Drugs and Elderly Patient Safety

Fineline Cube Mar 28, 2023

The National Center for ADR Monitoring has published its “National Adverse Drug Reaction Monitoring Annual...

Policy / Regulatory

China’s New Internet Advertising Regulations Impact Pharmaceutical Sector

Fineline Cube Mar 28, 2023

The State Administration for Market Regulation has released the latest version of the “Measures for...

Company

Fosun Pharma Reports 12.66% YOY Revenue Growth and Increased R&D Investment in 2022 Financial Report

Fineline Cube Mar 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...

Company Drug

CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China

Fineline Cube Mar 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has obtained an Emergency...

Company Medical Device

Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China

Fineline Cube Mar 27, 2023

US-based medical device leader, Boston Scientific Corporation (NYSE: BSX), has announced the market launch of...

Policy / Regulatory

CDE Launches Technical Guidelines for Pediatric Anti-tumor Drug Development

Fineline Cube Mar 27, 2023

The Center for Drug Evaluation (CDE) has released a set of Technical Guidelines focused on...

Company Deals

Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion and R&D

Fineline Cube Mar 27, 2023

China-based Huaren Pharmaceutical Co., Ltd (SHE: 300110) is set to raise capital through the private...

Policy / Regulatory

CDE Issues New Guidance on Pre-Phase III Clinical Trial Meetings for Innovative Drugs

Fineline Cube Mar 27, 2023

The Center for Drug Evaluation (CDE) has released the “Innovative Chemical Drug Pre-Phase III Clinical...

Company Deals

Zhaoke Ophthalmology Signs Distribution Agreement with Kwangdong for NVK002 in South Korea

Fineline Cube Mar 27, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Company Drug

Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Gain Clinical Trial Approvals

Fineline Cube Mar 27, 2023

China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...

Posts pagination

1 … 489 490 491 … 610

Recent updates

  • Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
  • Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%
  • Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic
  • Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination
  • Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.